drugset / Trial / NCT00133354
Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
Phase 2/3
Completed
53 enrolled
Nemours Children's Clinic
AstraZeneca · collabEMD Serono · collabGenentech, Inc. · collab
RandomizedParallel-groupQuadruple-blind
Summary
The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year trial.
Timeline
- Start
- 2001-11
- Primary completion
- 2006-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anastrozole | Other / unclassified | 1 mg | Oral |
| Comparator | Somatropin | Protein / enzyme biologic | 0.3 mg/kg | Subcutaneous |